LABELS · f4c6a69e-cc09-4328-a863-8c32a7f73a68

Solu-Medrol

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-03-18
Captured: 2026-09-09T23:38:04.335995+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

Full extracted label fields

application numbers

NDA011856

boxed warning exact

brand names

Solu-Medrol

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=decceb81-e922-4b72-a278-3ed80f4adb04

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

f4c6a69e-cc09-4328-a863-8c32a7f73a68

indications and usage exact

INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

indications and usage tables exact

is original packager

manufacturer names

Henry Schein, Inc.

matched search terms

cancer
lymphomas
tumor

package ndcs

0404-9958-01

product ndcs

0404-9958

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAMUSCULAR
INTRAVENOUS

rxcuis

207191
311659

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00800.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 738
end exclusive: true
exact text: INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary o
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 0

current approval status

not_reconciled

duplicate text group

dup-20112b0f7921b36f57f9

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-a85bae759f8f16311fbb

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

end: 274
end exclusive: true
exact text: is indicated
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 262

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 538
end exclusive: true
exact text: INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 907
end exclusive: true
exact text: allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where a
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 339

current approval status

not_reconciled

duplicate text group

dup-9442fd4329f12f74fe74

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-16855486c7510eb6df82

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 707
end exclusive: true
exact text: Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 539

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1291
end exclusive: true
exact text: ckness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders: Acquired (autoimmune) hemo
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 508

current approval status

not_reconciled

duplicate text group

dup-155fe9aaa037651dc243

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-32c3180e3bbacbeda354

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1091
end exclusive: true
exact text: Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 708

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1441
end exclusive: true
exact text: ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administ
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 892

current approval status

not_reconciled

duplicate text group

dup-fb1fbee03e46c78a8737

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-8c7cf0f9806c0470e0ff

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1241
end exclusive: true
exact text: Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1092

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · risk or warning

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1772
end exclusive: true
exact text: sociated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemoth
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1042

current approval status

not_reconciled

duplicate text group

dup-3ed142f7c81909eed646

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-0ec6fc904e315b263110

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

context exact
nd-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administrat
kind
age
polarity
not_inferred
span
end
1419
end exclusive
true
exact text
adults
label id
f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start
1413

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1572
end exclusive: true
exact text: Hemotologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1242

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1978
end exclusive: true
exact text: idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tu
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1373

current approval status

not_reconciled

duplicate text group

dup-700293771479c3167b73

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-01a2f55483c46550361b

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1778
end exclusive: true
exact text: Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1573

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2057
end exclusive: true
exact text: laneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and oc
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1579

current approval status

not_reconciled

duplicate text group

dup-81be0c30643005e02b40

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-a8df58f34e3e4f93f3bf

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1857
end exclusive: true
exact text: Neoplastic diseases: For the palliative management of leukemias and lymphomas.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1779

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2197
end exclusive: true
exact text: ingitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idio
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1658

current approval status

not_reconciled

duplicate text group

dup-82de8590b91ff9aeb317

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-a1bd1bb58258f6893cc1

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

context exact
ltiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy.
kind
biomarker
polarity
not_inferred
span
end
1981
end exclusive
true
exact text
metastatic brain tumor
label id
f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start
1959
context exact
ltiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy.
kind
stage_or_setting
polarity
not_inferred
span
end
1981
end exclusive
true
exact text
metastatic brain tumor
label id
f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start
1959

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1997
end exclusive: true
exact text: Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1858

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2326
end exclusive: true
exact text: : For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulm
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1798

current approval status

not_reconciled

duplicate text group

dup-da631b791a9a3838b659

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-e525c325a2c7727802ec

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2126
end exclusive: true
exact text: Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1998

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2458
end exclusive: true
exact text: dema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptom
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 1927

current approval status

not_reconciled

duplicate text group

dup-377fa3dd989c9a2054e1

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-87d6338c3ed8530dbf04

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2258
end exclusive: true
exact text: Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 2127

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2675
end exclusive: true
exact text: ar inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spo
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 2059

current approval status

not_reconciled

duplicate text group

dup-a3f9a9c520a723c2e778

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-28b5b43af138a3a3a6a6

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2475
end exclusive: true
exact text: Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 2259

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2932
end exclusive: true
exact text: ses: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 2276

current approval status

not_reconciled

duplicate text group

dup-7cad36e1b047df4bbc7a

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-028fd58ff93ffc69d8d0

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2826
end exclusive: true
exact text: Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 2476

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA011856

brand names

Solu-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2932
end exclusive: true
exact text: hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 2627

current approval status

not_reconciled

duplicate text group

dup-c2d36851a742917232ba

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE SODIUM SUCCINATE

ind-span-9fc07975d42407330b6d

label id

f4c6a69e-cc09-4328-a863-8c32a7f73a68

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2932
end exclusive: true
exact text: For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: f4c6a69e-cc09-4328-a863-8c32a7f73a68
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 70eb44218806a359f770129624a59aba6e38000378e89d2bd014c37b4dca5e24
start: 2827

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f4c6a69e-cc09-4328-a863-8c32a7f73a68%22

spl effective date

2026-03-18

spl set id

decceb81-e922-4b72-a278-3ed80f4adb04

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice